BeyondSpring posts investor deck highlighting plinabulin late-stage NSCLC program and immune-modulating approach

• BeyondSpring highlighted plinabulin as a late-stage immune modulator positioned for 2L/3L NSCLC, including post–PD-1/L1 progression.
• DUBLIN-3 Phase 3 (n=559) met its primary endpoint, showing OS HR 0.82; median OS 10.5 months vs 9.4 months.
• Trial data also showed PFS, ORR improvements; grade 4 neutropenia fell sharply, including 33.58% to 5.13% on day 8.
• Company outlined DUBLIN-4 confirmatory Phase 3 in non-squamous EGFR, ALK, ROS1, RET WT NSCLC post-immunotherapy; global N=442; primary endpoint OS.
• Study 303 in post-ICI metastatic NSCLC (n=47) reported confirmed ORR 18.2%; median PFS 7.0 months; 24-month OS 58%.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BeyondSpring Inc. published the original content used to generate this news brief on August 14, 2026, and is solely responsible for the information contained therein.